Development of a novel homogenous electrochemiluminescence assay for quantitation of ranibizumab in human serum

Journal of Pharmaceutical and Biomedical Analysis

Volumn 52, Issue 5, 2010, Pages 680-686

  Lowe, John ^a   Maia, Mauricio ^a   Wakshull, Eric ^a   Siguenza, Patricia ^a   Liu, Patrick ^a   Lakhani, Saleem ^a   Rusit, Jeriza ^a   Elliott, Rebecca ^a   Quarmby, Valerie ^a  

^a GENENTECH INC   (United States)

Author keywords

Electrochemiluminescence; Pharmacokinetics; Ranibizumab

Indexed keywords

IMMUNOGLOBULIN F(AB) FRAGMENT; RANIBIZUMAB; RUTHENIUM; STREPTAVIDIN; VASCULOTROPIN A;

ACCURACY; ANTIGEN ANTIBODY COMPLEX; ANTIGEN BINDING; ANTIGEN PURIFICATION; ARTICLE; BINDING AFFINITY; BIOTINYLATION; CHEMOLUMINESCENCE; CROSS REACTION; ELECTROCHEMOLUMINESCENCE ASSAY; ENZYME LINKED IMMUNOSORBENT ASSAY; FREEZE THAWING; HUMAN; INCUBATION TIME; INTERMETHOD COMPARISON; PRIORITY JOURNAL; PROCESS OPTIMIZATION; SENSITIVITY AND SPECIFICITY; VALIDITY;

ANTIBODIES, MONOCLONAL; ELECTROCHEMISTRY; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; LIMIT OF DETECTION; LUMINESCENCE; REPRODUCIBILITY OF RESULTS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 77950865363     PISSN: 07317085     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jpba.2010.01.048     Document Type: Article

References (28)

1. Bressler N.M. Age-related macular degeneration is the leading cause of blindness. JAMA 2004, 291:1900-1901.
2. Friedman D.S., O'Colmain B.J., Munoz B., Tomany S.C., McCarty C., de Jong P.T., Nemesure B., Mitchell P., Kempen J. Prevalence of age-related macular degeneration in the United States. Arch. Ophthalmol. 2004, 122:564-572.
3. Melnikova I. Wet age-related macular degeneration. Nat. Rev. Drug Discov. 2005, 4:711-712.
4. Ferris F.L., Fine S.L., Hyman L. Age-related macular degeneration and blindness due to neovascular maculopathy. Arch. Ophthalmol. 1984, 102:1640-1642.
5. Kliffen M., Sharma H.S., Mooy C.M., Kerkvliet S., de Jong P.T. Increased expression of angiogenic growth factors in age-related maculopathy. Br. J. Ophthalmol. 1997, 81:154-162.
6. Kvanta A., Algvere P.V., Berglin L., Seregard S. Subfoveal fibrovascular membranes in age-related macular degeneration express vascular endothelial growth factor. Invest. Ophthalmol. Vis. Sci. 1996, 37:1929-1934.
7. Lopez P.F., Sippy B.D., Lambert H.M., Thach A.B., Hinton D.R. Transdifferentiated retinal pigment epithelial cells are immunoreactive for vascular endothelial growth factor in surgically excised age-related macular degeneration-related choroidal neovascular membranes. Invest. Ophthalmol. Vis. Sci. 1996, 37:855-868.
8. Chen Y., Wiesmann C., Fuh G., Li B., Christinger H.W., McKay P., de Vos A.M., Lowman H.B. Selection and analysis of an optimized anti-VEGF antibody: crystal structure of an affinity-matured Fab in complex with antigen. J. Mol. Biol. 1999, 293:865-881.
9. Brown D.M., Michels M., Kaiser P.K., Heier J.S., Sy J.P., Ianchulev T. Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: two-year results of the ANCHOR study. Ophthalmology 2009, 116:57-65.
10. Kaiser P.K., Do D.V. Ranibizumab for the treatment of neovascular AMD. Int. J. Clin. Pract. 2007, 61:501-509.
11. Rosenfeld P.J., Brown D.M., Heier J.S., Boyer D.S., Kaiser P.K., Chung C.Y., Kim R.Y. Ranibizumab for neovascular age-related macular degeneration. N. Engl. J. Med. 2006, 355:1419-1431. for the MARINA Study Group.
12. Shih T., Lindley C. Bevacizumab: an angiogenesis inhibitor for the treatment of solid malignancies. Clin. Ther. 2006, 28:1779-1802.
13. Lowe J., Araujo J., Yang J., Reich M., Oldendorp A., Shiu V., Quarmby V., Lowman H., Lien S., Gaudreault J., Maia M. Ranibizumab inhibits multiple forms of biologically active vascular endothelial growth factor in vitro and in vivo. Exp. Eye Res. 2007, 85:425-430.
14. Gaudreault J., Fei D., Rusit J., Suboc P., Shiu V. Preclinical pharmacokinetics of ranibizumab (rhuFabV2) after a single intravitreal administration. Invest. Ophthalmol. Vis. Sci. 2005, 46:726-733.
15. DeSilva B., Smith W., Weiner R., Kelley M., Smolec J., Lee B., Khan M., Tacey R., Hill H., Celniker A. Recommendations for the bioanalytical method validation of ligand-binding assays to support pharmacokinetic assessments of macromolecules. Pharm. Res. 2003, 20:1885-1900.
16. Persselin J.E., Stevens R.H. Anti-Fab antibodies in humans. Predominance of minor immunoglobulin G subclasses in rheumatoid arthritis. J. Clin. Invest. 1985, 76:723-730.
17. Waller M., Duma R.J. Increased antibodies to IgG fragments: correlation with infection due to gram-positive bacteria. J. Infect. Dis. 1972, 125:45-53.
18. Birdsall H.H., Rossen R.D. Characterization of anti-Fab' antibodies in human sera: identification of soluble immune complexes that contain hidden anti-KLH and blocking anti-immunoglobulins following immunization with keyhole limpet haemocyanin. Clin. Exp. Immunol. 1983, 53:497-504.
19. Blackburn G.F., Shah H.P., Kenten J.H., Leland J., Kamin R.A., Link J., Peterman J., Powell M.J., Shah A., Talley D.B. Electrochemiluminescence detection for development of immunoassays and DNA probe assays for clinical diagnostics. Clin. Chem. 1991, 37:1534-1539.
20. Verschraegen I., Anckaert E., Schiettecatte J., Mees M., Garrido A., Hermsen D., Lentjes E.G., Liebert A., Roth H.J., Stamminger G., Smitz J. Multicenter evaluation of a rapid electrochemiluminescent adrenocorticotropic hormone (ACTH) immunoassay. Clin. Chim. Acta 2007, 380:75-80.
21. Findlay J.W., Smith W.C., Lee J.W., Nordblom G.D., Das I., DeSilva B.S., Khan M.N., Bowsher R.R. Validation of immunoassays for bioanalysis: a pharmaceutical industry perspective. J. Pharm. Biomed. Anal. 2000, 21:1249-1273.
22. Horninger D., Eirikis E., Pendley C., Giles-Komar J., Davis H.M., Miller B.E. A one-step, competitive electrochemiluminescence-based immunoassay method for the quantification of a fully human anti-TNFalpha antibody in human serum. J. Pharm. Biomed. Anal. 2005, 38:703-708.
23. Swanson S.J., Jacobs S.J., Mytych D., Shah C., Indelicato S.R., Bordens R.W. Applications for the new electrochemiluminescent (ECL) and biosensor technologies. Dev. Biol. Stand. 1999, 97:135-147.
24. Rosenfeld P.J., Schwartz S.D., Blumenkranz M.S., Miller J.W., Haller J.A., Reimann J.D., Greene W.L., Shams N. Maximum tolerated dose of a humanized anti-vascular endothelial growth factor antibody fragment for treating neovascular age-related macular degeneration. Ophthalmology 2005, 112:1048-1053.
25. Jelkmann W. Pitfalls in the measurement of circulating vascular endothelial growth factor. Clin. Chem. 2001, 47:617-623.
26. Zimmermann R., Koenig J., Zingsem J., Weisbach V., Strasser E., Ringwald J., Eckstein R. Effect of specimen anticoagulation on the measurement of circulating platelet-derived growth factors. Clin. Chem. 2005, 51:2365-2368.
27. Mock D.M., Mock N.I. Serum concentrations of bisnorbiotin and biotin sulfoxide increase during both acute and chronic biotin supplementation. J. Lab. Clin. Med. 1997, 129:384-388.
28. TM) in subjects with AMD. Presented at ARVO Annual Meeting 2005, (Abstract 1383).